home / stock / zyne / zyne quote
Last: | $1.30 |
---|---|
Change Percent: | 3.08% |
Open: | $1.26 |
Close: | $1.30 |
High: | $1.34 |
Low: | $1.26 |
Volume: | 862,786 |
Last Trade Date Time: | 10/10/2023 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.3 | $1.26 | $1.3 | $1.34 | $1.26 | 862,786 | 10-10-2023 |
$1.27 | $1.24 | $1.27 | $1.29 | $1.24 | 760,798 | 10-09-2023 |
$1.28 | $1.25 | $1.28 | $1.28 | $1.22 | 380,111 | 10-06-2023 |
$1.25 | $1.22 | $1.25 | $1.27 | $1.21 | 1,064,075 | 10-05-2023 |
$1.21 | $1.26 | $1.21 | $1.27 | $1.185 | 1,542,489 | 10-04-2023 |
$1.26 | $1.27 | $1.26 | $1.27 | $1.24 | 658,616 | 10-03-2023 |
$1.27 | $1.27 | $1.27 | $1.28 | $1.25 | 589,862 | 10-02-2023 |
$1.275 | $1.28 | $1.275 | $1.29 | $1.26 | 561,615 | 09-29-2023 |
$1.28 | $1.28 | $1.28 | $1.29 | $1.27 | 234,514 | 09-28-2023 |
$1.27 | $1.27 | $1.27 | $1.315 | $1.26 | 1,294,628 | 09-27-2023 |
$1.28 | $1.32 | $1.28 | $1.34 | $1.27 | 5,695,542 | 09-26-2023 |
$1.32 | $1.32 | $1.32 | $1.33 | $1.32 | 1,099,211 | 09-25-2023 |
$1.34 | $1.32 | $1.34 | $1.3416 | $1.32 | 603,578 | 09-22-2023 |
$1.34 | $1.33 | $1.34 | $1.36 | $1.3112 | 1,254,220 | 09-21-2023 |
$1.35 | $1.33 | $1.35 | $1.37 | $1.32 | 1,056,883 | 09-20-2023 |
$1.33 | $1.33 | $1.33 | $1.36 | $1.33 | 550,984 | 09-19-2023 |
$1.33 | $1.35 | $1.33 | $1.37 | $1.33 | 784,475 | 09-18-2023 |
$1.39 | $1.33 | $1.39 | $1.4 | $1.33 | 1,472,798 | 09-15-2023 |
$1.35 | $1.32 | $1.35 | $1.35 | $1.32 | 510,821 | 09-14-2023 |
$1.33 | $1.32 | $1.33 | $1.36 | $1.32 | 902,993 | 09-13-2023 |
News, Short Squeeze, Breakout and More Instantly...
Zynerba Pharmaceuticals Inc. Company Name:
ZYNE Stock Symbol:
NASDAQ Market:
Healthcare company Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) completed its previously announced acquisition of Zynerba Pharmaceuticals, Inc...
HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE PR Newswire New product in development diversifies portfolio to drive long-term growth Innovative potential new therapeutic option for rare/orphan neuropsychiatric disorders w...
DEVON, Pa., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced tr...